Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Studies of NVP-BEZ235 in Melanoma

Author(s): Joshua A. Sznol, Lucia B. Jilaveanu and Harriet M. Kluger

Volume 13, Issue 2, 2013

Page: [165 - 174] Pages: 10

DOI: 10.2174/1568009611313020006

Price: $65

Abstract

The PI3k pathway represents an attractive target for drug development in melanoma, as numerous studies have shown that this pathway is active in malignant melanocytes. In addition, previous work has shown that multi-level targeting of this pathway might be more effective than targeting the pathway at a single level. In this review, we discuss targeting different members of this pathway, potential escape mechanisms, classes of specific molecular inhibitors, and development of NVP-BEZ235, a novel dual PI3k/mTOR inhibitor.

Keywords: Mammalian target of rapamycin, melanoma, phosphatidylinositol 3-kinase.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy